Freenome is a biotechnology company that leverages artificial intelligence and machine learning to develop a multiomics platform for early cancer detection and precision medicine. Founded in 2014, Freenome is headquartered in South San Francisco, California. With a dedicated team of over 200 employees, the company focuses on advancing the understanding of diseases through the analysis of genomic and proteomic data.

Freenome's platform combines genomic sequencing, proteomics, and machine learning algorithms to detect early signs of cancer and guide personalized treatment decisions. By analyzing blood samples, they aim to identify molecular signatures and biomarkers associated with cancer and other diseases, enabling proactive interventions and tailored therapies.

Freenome has attracted over $1 billion in funding. However, it is recommended to visit Freenome's official website for the most up-to-date financial details.